The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows | Facebook

Test Oncotype DX Breast Recurrence Score®: test genomowy dla kobiet z rakiem piersi

A routine eye exam found Stage 1 colon cancer

6 comments | For Bola, cancer has been “extremely eye-opening.” “I have learned to embrace every single day.” —Bola, breast cancer survivor and Oncotype DX® Ambassador Tell us, how has cancer changed you? | Until Everyone Knows | Facebook

When most people hear #cancer, they immediately believe they need #chemotherapy. But chemotherapy may not be needed for all people diagnosed with breast cancer. That’s where the Oncotype DX Breast Recurrence Score® test comes into play: The test can help determine if someone will benefit from chemotherapy—or if they can safely forgo it. Learn more: https://bit.ly/3ZvYFWO #BreastCancer #CancerTreatment | Until Everyone Knows | Facebook